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ABSTRACT
A cross-sectional analysis of human papillomavirus (HPV) vaccine statutes and regulations from states
and the District of Columbia in the United States (U.S.) was conducted from September–November 2018
to advance analyses of policy impact on HPV vaccination uptake. A search was conducted using
WestlawNext, a legal research database. Statutes and regulations relevant to the study were analyzed
and coded based on their legal attributes into ten broad coding questions and several sub-questions. Of
the 212 laws identified by the initial search string, 93 (43.9%) reference HPV vaccination in statute or
regulation. An additional three laws were added following subsequent review. There was a total of 52
statutes and 44 regulations from 34 states and the District of Columbia. Most laws were related to
developing and distributing HPV vaccination materials for parents, and mechanisms to fund and
reimburse for the vaccination. This study can be used by policymakers in jurisdictions that are consider-
ing establishing HPV vaccination promotion interventions in state law and highlighting the limited
statutory and regulatory efforts that have been implemented to promote HPV vaccination. Importantly,
this study can also be used to conduct evaluations of the efficacy of statutory and regulatory strategies
in increasing HPV vaccination rates.
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Introduction
The vaccine to prevent human papillomavirus (HPV) related
cancers has been approved for use in the United States since
2006.1 As of 2017, the national coverage for ≥1 dose of HPV
vaccine among adolescents was 65.5% overall.2 There are lower
levels of uptake among teens living in non-metropolitan statistical
areas (MSA) compared to those living in MSA principal cities
(59.3% vs. 70.1%).2 Those living below the poverty level have
higher vaccination rates compared to those at or above the poverty
level (73.3% vs 53.7%).2 There are continued increases in uptake
amongboys (62.6% in 2017 comparedwith 56.0% in 2016).2While
not as high as compared with countries such as Australia, which
has projected the near elimination of cervical cancer within the
next 10 years,3 HPV vaccine uptake in the United States has
improved over time. However, it has been hampered by the lack
of a unified approach to vaccination both across and within states.
This diversity is reflected in the variation of vaccination rates
across states and regions with Northeastern, Midwestern, and
Western states seeing higher rates of HPV vaccination coverage
than Southern and Southwestern.2,4,5 Several studies have
attempted to demonstrate the impact of state policies on vaccine
uptake; focusing on particular states and specific policies such as
HPV vaccine school-entry requirements6–8 or policies requiring
vaccine education for parents.8,9 As observed by Durham et al.,10
and Roberts et al.,11 variability in HPV vaccine uptake across the
United States is probably a function, at least in part, of a collection
of structural elements, such as law and policy.
It is at this juncture that a full description of HPV vaccine
policies and laws is needed. Over the years, organizations such
as the National Conference of State Legislatures (NCSL) and
Immunization Action Coalition have conducted reviews of
introduced and enacted state legislation focused on HPV
vaccine.12,13 Researchers have also explored state require-
ments related to HPV vaccination and school-entry
requirements6–8 and pharmacist vaccination authority;14–17
providing analyses of the political, social, and ethical consid-
erations related to HPV vaccine mandates.18–23 Still, others
focused on administrative aspects of policy affecting vaccine
access24 and their impact on vaccination rates.11
While helpful, some of this research focuses exclusively on
legislative activity.25,26 Additionally, much of the existing HPV
vaccination law literature relies on data generated by
NCSL.8,9,11,21,26,27 While this information is incredibly valuable
for strategic planning, developing policy priorities, and giving an
idea of the existing landscape of laws, it cannot be relied on for
scientific studies. NCSL largely reviews legislation and not reg-
ulation, which is a serious limitation given that state legislatures
often delegate broad rulemaking authority to agencies to pro-
mote public health.28 And, vaccination requirements are regu-
larly passed via agency rulemaking, including HPV vaccination
requirements in states like Rhode Island and Virginia, among
others.29 NCSL does not (1) outline search strings; database or
databases used; (2) dates searches were conducted (currently the
site only includes the date in which the page was updated).
Because of these issues, NCSL cannot truly provide sound
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empirical data on which to base a study whose methodology and
analyses can be reproduced.30–32
The need for a comprehensive description of state law
across all subject areas from school requirements to vaccine
access, to funding would help advance analyses of policy
impact on HPV vaccination uptake. Additionally, there is
a need for an analysis that includes both statutes (law enacted
by legislatures and signed by governors) and regulations (law
developed by state agencies and associated with statute) given
that both mechanisms are used to advance HPV vaccination.
Finally, developments in the field of legal epidemiology – “the
scientific study and deployment of law as a factor in the cause,
distribution, and prevention of disease and injury in
a population” – have identified best practices for systemati-
cally conducting and analyzing laws in relation to public
health.33 This study implements these best practices. To the
best of our knowledge, this is the first study of state HPV
vaccination requirements that derived data using legal epide-
miological methods across statutes and regulations on
a breadth of topical areas including mandates, education,
scope of practice, and financing.
Here we describe the results of a cross-sectional analysis of
U.S. state (including DC) statutes and regulations related to
HPV vaccination collected in September – November 2018.
The analysis identified state laws currently in effect in fall,
2018 regardless of their initial effective date. These statutes
and regulations were analyzed and coded based on their legal
attributes into ten broad coding questions and several sub-
questions (Table 1). Additionally, this article – because it
specifically highlights references to HPV in statutes and reg-
ulations at the state level – identifies how legislatures and
agencies prioritize HPV vaccination-related issues regardless
of federal policies. For the purpose of this article, we will refer
to both statutes and regulations as laws given that they are
both legally binding and states use both mechanisms to estab-
lish vaccination requirements.
Results
Of the 212 laws pulled from the search, 93 (43.9%) reference
HPV vaccination in statute or regulation in 34 states and the
District of Columbia. An additional three provisions were
included in the results that clarified or expanded on provi-
sions that were already collected. There are 52 statutes and 44
regulations in total (Table 2). State laws focus on a number of
issues around HPV vaccination including vaccine finance,
school-entry requirement, vaccine recommendation, public
awareness, program development, vaccine access, vaccine
education, plan development, and vaccine reporting.
Of the jurisdictions with law focused on HPV vaccination,
only DC, Virginia and Rhode Island mandate HPV vaccination
as a condition for school attendance. (Table 3) While Rhode
Island and DC’s laws are gender neutral, Virginia’s is specific to
female students only. DC’s law specifically references CDC vac-
cination standards and, while all states allow school vaccination
exemptions, DC and Virginia create a specific parental opt-out
for HPV vaccination. For example, Virginia’s administrative
code states: “Because the human papillomavirus is not commu-
nicable in a school setting, a parent or guardian, at the parent’s or
guardian’s sole discretion, may elect for the parent’s or guar-
dian’s child not to receive the HPV vaccine.” Four other states
(Arizona, Louisiana, South Carolina, West Virginia) explicitly
exclude HPV vaccination from school vaccination requirements.
Table 1. Coding questions and sub-questions.
Question Code
I. Does state law reference HPV Vaccination? No
Yes
II. Does state law mandate HPV vaccination as a requirement for school entry? No
Yes
II.A If no, does state law exclude HPV vaccination as a requirement for school entry? No
Yes
II.B If no, does state law recommend HPV vaccination or require the development and distribution of materials regarding the HPV
vaccination to or for parents?
Offer
Recommend
Education
III. Does state law incorporate HPV vaccination into its educational curriculum? No
Yes
IV. Does state law establish other HPV vaccination requirements for children? Youth Camp
Assessment
Foster Care
V. Does state law establish laws related to consent by minors for STI vaccination? No
Yes
VI. Does state law expressly provide pharmacists with the authority to vaccinate for HPV? No
Yes
VII. Under state law, is HPV vaccination explicitly required to be covered by individual or group insurance plans? No
Yes
VIII. Does state law establish other mechanisms to cover, fund, or reimburse for HPV vaccination? No
Yes
IX. Does state law require the reporting of HPV vaccination data? No
Yes
X. Does state statute or regulation establish special measures, task forces, or special awareness activities related to cervical cancer
vaccination?
Public Awareness
State Agency
Program
Strategic Plan
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While only three jurisdictions require HPV vaccination
as a condition for school attendance under state law, other
states have established additional strategies to promote
HPV vaccination in school children. (Table 3) Four states
(Arkansas, Delaware, West Virginia, Wyoming) recommend
HPV vaccination in law. South Carolina allows its
Department of Health and Environmental Control to offer
HPV vaccination to adolescent students. Additionally, 12
states require or recommend the development or distribu-
tion of information to parents related to HPV vaccination
for parents. Two states (Iowa and Texas) require HPV
vaccination information to be incorporated into education
curricula.
States also have laws that promote childhood vaccination
in non-educational settings. This includes the requirement in
Maine that youth camps and similar programs assess HPV
vaccination status of their campers. Arkansas requires foster
parents to assist in ensuring children are vaccinated for
recommended vaccinations, including HPV.
Laws that seek to improve HPV vaccine access include
those that provide vaccination authority to pharmacists
and allow minors the ability to give consent for the vacci-
nation (Table 4). Five states (Hawaii, Indiana, Iowa, West
Virginia, Wyoming) and Washington DC expressly pro-
vide pharmacists with the authority to vaccinate for HPV
by listing it in law. As noted by Dingman & Schmit, many
states provide general authority to vaccinate without list-
ing each vaccine-preventable disease by name. The express
listing of HPV indicates that state legislators and agencies
specifically considered HPV in their policymaking
process.14
Illinois allows minors 12 years or older to consent to HPV
vaccination and Utah allows minors to consent if they are an
abandoned minor as represented by the patient. Some juris-
dictions require individual and group health insurance plans
to cover HPV vaccination while numerous states require HPV
vaccine coverage via Medicaid and other health programs.
These laws assure the coverage of HPV vaccination by indi-
vidual, group, HMO, and health benefit insurance plans via
Medicaid, or through other public health programs such as
public health or family planning (Alaska, Colorado, Illinois,
Louisiana, Maine, Maryland, Massachusetts, Mississippi,
Nevada, New Hampshire, New Mexico, Ohio, Oklahoma,
Oregon, Pennsylvania, and West Virginia).
Finally, public health strategies are also incorporated into
statutes and regulations. West Virginia and Washington DC
require their departments of health to collect HPV vaccina-
tion data. Colorado, North Dakota, Texas, and Washington
DC require public awareness activities. Further, Colorado,
Illinois, and Indiana require the establishment of department
of health programs or strategic plans that include activities
related to HPV vaccination.
No single coding question included results from more than
one-third of the jurisdictions, and many states had laws
related only to one aspect of HPV access such as educational
materials or vaccine financing. Eight of the ten coding ques-
tions included results from six or fewer states. The coding
questions that had the most state activity were related to
developing and distributing HPV vaccination materials for
parents and those related to mechanisms to fund and reim-
burse for the vaccination.
Table 2. Reference to HPV vaccination in relevant statutes and regulations by
U.S. States and the District of Columbia, 2018.
State
State Law References HPV
Vaccination
# of
Statutes*
# of
Regulations*
Alabama No 0 0
Alaska Yes 0 1
Arizona Yes 1 0
Arkansas Yes 0 2
California No 0 0
Colorado Yes 5 1
Connecticut No 0 0
Delaware Yes 0 1
Florida No 0 0
Georgia No 0 0
Hawaii Yes 4 0
Idaho No 0 0
Illinois Yes 3 1
Indiana Yes 3 0
Iowa Yes 3 0
Kansas No 0 0
Kentucky No 0 0
Louisiana Yes 1 4
Maine Yes 0 6
Maryland Yes 0 1
Massachusetts Yes 0 2
Michigan Yes 2 0
Minnesota No 0 0
Mississippi Yes 0 1
Missouri Yes 1 0
Montana No 0 0
Nebraska No 0 0
Nevada Yes 9 0
New
Hampshire
Yes 0 1
New Jersey Yes 1 0
New Mexico Yes 2 0
New York No 0 0
North
Carolina
Yes 5 0
North Dakota Yes 1 0
Ohio Yes 0 1
Oklahoma Yes 0 1
Oregon Yes 1 2
Pennsylvania Yes 2 0
Rhode Island Yes 0 1
South
Carolina
Yes 1 0
South Dakota No 0 0
Tennessee No 0 0
Texas Yes 2 0
Utah Yes 1 0
Vermont No 0 0
Virginia Yes 1 5
Washington Yes 1 0
West Virginia Yes 0 7
Wisconsin No 0 0
Wyoming Yes 0 3
Washington
DC
Yes 2 3
*Laws may include the similar language or requirements across separate indivi-
dual provisions.
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Discussion
Despite finding that 34 states and the District of Columbia
reference HPV vaccination in statutes or regulation, there
were remarkably few state laws on this topic, and few states
with laws across multiple coding categories as outlined above.
The observation that HPV vaccination education was
a common policy outcome among states enacting law related
to HPV vaccination may be an artifact of what Abiola et al.
observed: that vaccine education policy emerged as
a negotiated outcome in 2006 state legislative policy processes
due to the initiation of an HPV vaccination policy agenda by
Merck and Women in Government, the non-partisan associa-
tion of women state legislators.23 Findings from our study sug-
gest continued state reluctance to develop a policy to expand
HPV vaccination. However, the fact that 17 states implemented
financing policy to expand HPV vaccine access may indicate
that, today in the United States, healthcare financing of HPV
vaccination is the most achievable policy change and has bene-
fits, because such policy structurally impacts access to HPV
vaccination uptake as shown in populations that are usually
un/underinsured.2 These more innocuous, but potentially
impactful policies may, in fact, change the HPV vaccination
environment, despite the fact that the majority of states have
not made HPV vaccination the “default choice.”34
Even within the states that have a number of HPV vaccina-
tion-related laws, one cannot presume that a higher number of
statutes and regulations indicates a comparatively higher com-
mitment to improving HPV vaccination access across states.
This is because individual states and individual acts or rulemak-
ing within a state can vary substantially in terms of the length of
a single provision when it is codified. For example, a state with
ten provisions is not necessarily more active than a state with
two, if the two provisions run for a much longer period than the
ten. Further, the number of results generated in the collection of
laws for this study might be a function of the search, where
search strings can be crafted more narrowly or more broadly
with adjustments in the terms and connectors. While the num-
ber of provisions is not necessarily an indicator of commitment,
the study found that there were nearly as many individual
regulatory provisions in our results as individual statutory pro-
visions. This reinforces the value of research across both legisla-
tion and rulemaking.
Overwhelmingly, jurisdictions tend to use statutes and
regulations to promote HPV vaccination, such as financial
incentives or requirements for public education campaigns
as opposed to laws that limited vaccination. However, there
are still laws that function in practice to curb vaccination.
State laws that explicitly exclude HPV vaccination from
school-entry requirements and those in DC and Virginia
that create an express parental opt-out for the vaccination
are such examples. Opt-out provisions that provide so much
discretion to parents on HPV vaccination that, in practice,
there is no realistic way to enforce the requirements.35–38
Another emerging issue which has been explored elsewhere
is the tendency to focus on females for HPV related policy
and interventions.38–41 Virginia’s language of limiting its
Table 3. States with laws related to school entry, parental education, U.S. States and District of Columbia – 2018.
State law mandates
HPV vaccination as
school-entry
requirement
State law excludes
HPV vaccination as
school-entry
requirement
State law
recommends HPV
vaccination for
school children
State law requires the
development and distribution of
materials regarding the HPV
vaccination to parents
State law allows the
department of
health to offer HPV
to students
State law requires
incorporation of HPV
vaccination information
into educational
curriculum
Arizona X
Arkansas X
Delaware X
Illinois X
Indiana X
Iowa X
Louisiana X X
Michigan X
Missouri X
New Jersey X
North
Carolina
X
Rhode
Island
X
South
Carolina
X X X
Texas X X
Virginia X X
Washington X
West
Virginia
X X
Wyoming X
Washington
DC
X X
State Total 3 4 4 12 1 2
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school-entry requirements to only female students does not
reflect CDC guidelines41 and shifts the burden of cervical
cancer prevention entirely to female students. As we note
elsewhere,40 this is likely reflective of the changing science
around HPV and the delay in reflecting such science in policy,
as Virginia enacted this law in 2007,9 the same year that
CDC’s Advisory Community on Immunization Practices
(ACIP) issued its first recommendations related to HPV
vaccination.42 These recommendations exclusively applied to
females.42 Following evolving data on the efficacy of HPV in
clinical trials, ACIP’s recommendations and guidelines began
contemplating male vaccination in 2009 with additional
changes in policy in subsequent years.43 DC’s statutory code
contemplates both male and female students in their school
vaccination statute, and its regulatory code applies neutrally to
students generally. Similarly, Rhode Island’s regulatory code
establishes vaccination requirements for students without
reference to gender. That said, a study of the gendering of
HPV vaccination law across time would be an important
contribution to the literature.
This study is subject to several limitations. First, other
mechanisms independent of statutes and regulations can be
used to promote HPV vaccination that was not collected as
part of this study. This includes state agency policies such as
state cancer plans, local government actions, and case law.
Nor does this study include a summary of all federal laws
that might impact HPV vaccination. Additionally, the study
did not analyze the funding, implementation, or enforce-
ment of these laws, which affect the impact of these laws in
practice.
Next, laws that do not expressly reference HPV vaccination
can also be relevant to HPV vaccination promotion. For
example, laws that promote cancer and sexually transmitted
infection prevention or those that fund public health preven-
tion activities might impact HPV vaccination rates. There is,
for example, some evidence that non-targeted adolescent vac-
cine school requirements may in fact impact HPV vaccination
rates.7
This study can be used by policymakers in jurisdictions
that are considering establishing HPV vaccination promotion
interventions in state law and highlighting the limited statu-
tory and regulatory efforts that have been implemented to
promote HPV vaccination. Importantly, this study can also be
used to conduct evaluations of the efficacy of statutory and
regulatory strategies in increasing HPV vaccination rates.
Methods
This study utilized legal epidemiological research methods to
collect and analyze statutes and regulations.30–33 These prac-
tices include utilizing a standardized search string; utilizing
the same database or databases to collect laws across all
jurisdictions, developing inclusion and exclusion criteria, pre-
serving laws separately from the database in the event of
changes to the language, and developing a detailed research
procedure that can be made available to a requestor.30–33
Statutes and regulations from the 50 states and
Washington, DC, were collected on September 3, 2018 using
WestlawNext, an online legal database. The following search
string was crafted based on the database’s terms, connectors
Table 4. States with laws that promote vaccine access, U.S. States and District of Columbia – 2018.
State law allows
consent by minors for
STI vaccination
State law expressly provides
pharmacists with the authority to
vaccinate for HPV
HPV vaccination is explicitly required to be
covered by individual or group insurance
plans under state law
State law establishes other
mechanisms to cover, fund, or
reimburse for HPV vaccination
Alaska X
Colorado X X
Hawaii X
Illinois X X X
Indiana X
Iowa X
Louisiana X
Maine X
Maryland X
Massachusetts X
Mississippi X
Nevada X X
New
Hampshire
X
New Mexico X X
Ohio X
Oklahoma X
Oregon X
Pennsylvania X
Utah X
West Virginia X X
Wyoming X
Washington
DC
X
State Total 2 6 5 15
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and relevant terminology to identify laws that referenced HPV
vaccination: adv: SD((cancer/5 vaccin! immuniz!) (s.t.i. s.t.d.
“sexual health” “sexually transmitted infection” “sexually
transmitted disease”/5 vaccin! immuniz!) h.p.v. “human papil-
lomavirus” gardasil cervarix).
From this search, 212 statutes and regulations were identi-
fied. Following an initial review of these laws, additional
statutes and regulations were added to the dataset when
referenced in the provisions already collected and were rele-
vant to HPV vaccination, or when additional provisions from
the same sections or chapters of the code clarified the require-
ments of the original statutes and regulations. These were
collected in October and November 2018. All statutes and
regulations generated from the search were preserved in pdf
format, and the research process was recorded in a research
procedure document.
Inclusion criteria were developed following a research team
conference and held that only laws expressly referencing HPV
vaccination were considered relevant in this study (Table 5).
Thus, for example, provisions that referenced HPV in the
context of screening and testing but did not mention vaccina-
tion were excluded. At least two additional laws that men-
tioned HPV vaccination but were found to be both unique to
the specific jurisdiction’s administrative or procedural process
in that state were also excluded from the analysis. These
included a provision related to the exemption of HPV vacci-
nation in an immunization registry and the certification of the
HPV vaccination as safe by a department of health. These
exclusion criteria were documented in the research procedure.
Statutes and regulations relevant to the study were ana-
lyzed and coded based on their legal attributes into ten broad
coding questions and several sub-questions (Table 1). These
Table 5. Inclusion and exclusion criteria flow chart.
Collect all laws that reference 
HPV or a variation of the term.
Upon review of these laws: 
Does the law reference HPV in 
the context of vaccination?
If yes, include the law in the 
study.
Does the law reference HPV 
vaccine in the context that is 
unique to a particular state's 
administrative or procedural 
process?
If yes, exclude from the 
study.
Examples: a provision related 
to the exemption of HPV 
vaccination in an 
immunization registry and 
the certification of the HPV 
vaccination as safe by a 
department of health  
If no, include in the study.
If no, exclude the law from 
this study.
Example: provisions that 
referenced HPV in the 
context of screening and 
testing but did not mention 
vaccination
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coding questions were revised as nuances across states were
identified. The analysis sought to describe the legal attributes,
variabilities, and nuances in the laws across jurisdictions.
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